北大医药:持股11.80%的股东北大医疗计划自2025年10月14日至2026年1月11日,以集中竞价和大宗交易方式合计减持不超过1787.96万股,占公司总股本3%。其中,通过集中竞价方式减持不超595.99万股,占1%;通过大宗交易方式减持不超1191.97万股,占2%。百洋医药:公司与济坤医药及其实际控制人签署了战略合作协议。根据协议,百洋医药拟参与济坤医药增资扩股,预计将持有济坤医药24%...
Source Link北大医药:持股11.80%的股东北大医疗计划自2025年10月14日至2026年1月11日,以集中竞价和大宗交易方式合计减持不超过1787.96万股,占公司总股本3%。其中,通过集中竞价方式减持不超595.99万股,占1%;通过大宗交易方式减持不超1191.97万股,占2%。百洋医药:公司与济坤医药及其实际控制人签署了战略合作协议。根据协议,百洋医药拟参与济坤医药增资扩股,预计将持有济坤医药24%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.